Wang, J., Zhang, Q., Li, H., Tong, Z., Ouyang, Q., Li, H., . . . Xu, B. (2025). Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy. Nature Communications, 16(1), 1. https://doi.org/10.1038/s41467-025-58647-z
Chicago-referens (17:e uppl.)Wang, Jiayu, et al. "Bireociclib Plus Fulvestrant for HR+/HER2- Advanced Female Breast Cancer Progressed on or After Endocrine Therapy." Nature Communications 16, no. 1 (2025): 1. https://doi.org/10.1038/s41467-025-58647-z.
MLA-referens (9:e uppl.)Wang, Jiayu, et al. "Bireociclib Plus Fulvestrant for HR+/HER2- Advanced Female Breast Cancer Progressed on or After Endocrine Therapy." Nature Communications, vol. 16, no. 1, 2025, p. 1, https://doi.org/10.1038/s41467-025-58647-z.
